Inventor · disambiguated record
Harry Rogoff
Also filed as: ROGOFF HARRY
9 granted patents·12 pending applications·71 citations·filing 2006–2021
87Inventor score
Files withBOSTON BIOMEDICAL INC11LI CHIANG JIA41GLOBE HEALTH INST LLC31 GLOBE HEALTH INST LLC1LI CHIANG J1
Top patents by PatentIndex Score
21 records- 0195US9328345B2Compositions of asymmetric interfering RNA and uses thereofLI CHIANG JIA·Filed 2008·Granted May 3, 2016·42 cites·31 claims
- 0289US9745278B2Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitorsLI CHIANG JIA·Filed 2008·Granted Aug 29, 2017·7 cites·53 claims
- 0389US8299106B2Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinasesLI CHIANG JIA·Filed 2008·Granted Oct 30, 2012·12 cites·6 claims
- 0483US10927376B2Compositions of asymmetric interfering RNA and uses thereof1GLOBE HEALTH INST LLC·Filed 2019·Granted Feb 23, 2021·3 cites·34 claims
- 0581US11015195B2Compositions of asymmetric interfering RNA and uses thereof1GLOBE HEALTH INST LLC·Filed 2019·Granted May 25, 2021·2 cites·36 claims
- 0680US9187454B2Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereofBOSTON BIOMEDICAL INC·Filed 2014·Granted Nov 17, 2015·4 cites·18 claims
- 0775US12344840B2Compositions of asymmetric interfering RNA and uses thereof1GLOBE HEALTH INST LLC·Filed 2021·Granted Jul 1, 2025·0 cites·27 claims
- 0874US2021024482A1Novel Group of STAT3 Pathway Inhibitors and Cancer Stem Cell Pathway InhibitorsSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 0971US2020039948A1Novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitorsBOSTON BIOMEDICAL INC·Filed 2018·Application pending·0 cites
- 1068US10266821B2Compositions of asymmetric interfering RNA and uses thereof1 GLOBE HEALTH INST LLC·Filed 2016·Granted Apr 23, 2019·1 cites·32 claims
- 1167US2018030022A1Novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitorsBOSTON BIOMEDICAL INC·Filed 2017·Application pending·0 cites
- 1262US9725444B2Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinasesBOSTON BIOMEDICAL INC·Filed 2014·Granted Aug 8, 2017·0 cites·18 claims
- 1362US2019248781A1Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinasesBOSTON BIOMEDICAL INC·Filed 2018·Application pending·0 cites
- 1459US2018022743A1Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinasesBOSTON BIOMEDICAL INC·Filed 2017·Application pending·0 cites
- 1558US2012321622A1Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to KinasesLI CHIANG JIA·Filed 2012·Application pending·0 cites
- 1648US2016031888A13-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancerBOSTON BIOMEDICAL INC·Filed 2014·Application pending·0 cites
- 1747US2019241569A13-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancerBOSTON BIOMEDICAL INC·Filed 2018·Application pending·0 cites
- 1845US2019249134A1Cell cultures and use thereofBOSTON BIOMEDICAL INC·Filed 2018·Application pending·0 cites
- 1943US2018250261A1Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitorBOSTON BIOMEDICAL INC·Filed 2016·Application pending·0 cites
- 2042US2006204993A1Methods and compositions for modulating CHK2 pathways and methods for screening for sameLI CHIANG J·Filed 2006·Application pending·0 cites
- 2138US2018140572A1Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancerBOSTON BIOMEDICAL INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Harry Rogoff files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →